 |
NEWS RELEASE |
| CONTACT: | |
| CONMED Corporation | |
| Robert Shallish | |
| Chief Financial Officer | |
| 315-624-3206 |
FOR RELEASE: 7:00 AM (Eastern) July 24, 2013
CONMED Corporation Announces Second Quarter 2013 Financial Results
- EPS equals $0.34
- Adjusted EPS equals $0.43
Conference Call to be Held at 10:00 a.m. ET Today
Utica, New York, July 24, 2013 ----- CONMED Corporation (Nasdaq: CNMD) today announced financial results for the second quarter ended June 30, 2013.
“We met our previously forecasted revenues and earnings in the second quarter of 2013 despite a challenging global economy affecting healthcare utilization and hospital capital spending,” commented Mr. Joseph J. Corasanti, President and CEO. “Having a broad product portfolio such as ours is extremely beneficial in this environment. It allows us to meet our customers’ needs and to take advantage of opportunities as evidenced by the strong showing this quarter in the Surgical Visualization product line.”
Second Quarter 2013 Financial Highlights:
| · | Sales were $193.0 million, an increase of 1.7% (0.1% organic) and 2.3% in constant currency over the second quarter of 2012 |
| · | Diluted earnings per share (GAAP) were $0.34 compared to $0.36 in the second quarter of 2012 (excluding the medical device excise tax or “MDET,” EPS would have been $0.37 in 2013) |
| · | Adjusted diluted earnings per share were $0.43 in the second quarters of both years (excluding the MDET, adjusted EPS would have been $0.46 in 2013) |
| · | Adjusted EBITDA margin was 16.9%, a decrease of 20 basis points, caused by a 70 basis point negative effect from the MDET offset by operating improvements |
Six Months 2013 Financial Highlights
| · | Sales were $380.0 million compared to $384.0 million, a decrease of 1.0% (decrease of 2.2% organic) and a decrease of 0.5% in constant currency |
| · | Diluted earnings per share (GAAP) were $0.71 in both six month periods (excluding the MDET, EPS would have been $0.78 in 2013) |
| · | Adjusted diluted earnings per share grew to $0.88 compared to $0.85 in the first six months of 2012 (excluding the MDET, EPS would have been $0.94 in 2013) |
| CONMED News Release Continued | Page 2 of 12 | July 24, 2013 |
| · | Adjusted EBITDA margin was 17.0%, a decrease of 10 basis points, even with an 80 basis point negative effect from the MDET offset by operating improvements |
International sales in the second quarter of 2013 were $100.0 million, representing 51.8% of total sales. Foreign currency exchange rates including the effects of the FX hedging program caused sales to be $1.1 million less in the second quarter of 2013 compared to sales in the second quarter of 2012.
Cash provided by operating activities increased sequentially from the first quarter 2013 and equaled $17.7 million. For the six months ended June 2013, cash provided by operating activities was $23.2 million. The Company repurchased 582,000 shares of its common stock in the second quarter of 2013 and 1,431,000 shares in the first half of 2013 for $19.0 million and $44.7 million, respectively.
Outlook
“As we look to the rest of 2013, we anticipate continuation of current healthcare trends represented by flat to slightly negative healthcare utilization in the U.S. combined with governmental spending controls in major European countries. While we believe there may be slight moderation of these trends toward the end of 2013, we believe it prudent to tighten our full year 2013 adjusted earnings per share guidance by reducing the top end of the previous guidance range to $1.80 - $1.85 from the former $1.80 - $1.90 per share. This forecast contemplates the effects of the medical device tax and less favorable FX exchange rates,” said Mr. Corasanti. “Similarly, we now tighten the forecasted sales range to $770 - $775 million from the prior $770 - $780 million.”
“For the third quarter of 2013, we anticipate sales will approximate $184 - $189 million and adjusted earnings per share are forecasted to be $0.37 - $0.42,” continued Mr. Corasanti.
The adjusted estimates for the third quarter and full year 2013 exclude special items, such as manufacturing restructuring costs expected to be incurred in 2013 due to the relocation of manufacturing activities from the Westborough, Massachusetts and Tampere, Finland sites to the Company’s other facilities and patent litigation.
Special charges
During the second quarter of 2013, the Company continued the on-going consolidation of certain administrative functions and manufacturing activities. Also incurred were litigation costs associated with a patent matter. Expenses associated with these activities, including severance and relocation costs, amounted to $2.4 million, net of tax, in the second quarter of 2013. These charges are included in the GAAP earnings per share set forth above and are excluded from the adjusted results. For the remainder of 2013, the Company presently anticipates incurring additional pre-tax special costs of $6.5 - $7.5 million on projects currently in process.
Use of non-GAAP financial measures
Management has disclosed adjusted financial measurements in this press announcement that present financial information that is not in accordance with generally accepted accounting principles. These measurements are not a substitute for GAAP measurements, although Company management uses these measurements as aids in monitoring the Company’s on-going financial performance from quarter-to-quarter and year-to-year on a regular basis, and for benchmarking against other medical technology companies. Adjusted net income, adjusted operating income and adjusted earnings per share measure the income of the Company excluding credits or charges that are considered by management to be outside of the normal on-going operations of the Company. Management uses and presents adjusted net income, adjusted operating margin and adjusted earnings per share because management believes that in order to properly understand the Company’s short and long-term financial trends, the impact of special items should be eliminated from on-going operating activities. These adjustments for special items are derived from facts and circumstances that vary in frequency and impact on the Company’s results of operations. Management uses adjusted net income, adjusted operating income and adjusted earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consistent basis. Further, the presentation of EBITDA is a non-GAAP measurement that management considers useful for measuring aspects of the Company’s cash flow. Adjusted financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider adjusted measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
| CONMED News Release Continued | Page 3 of 12 | July 24, 2013 |
Conference call
The Company will webcast its second quarter 2013 conference call live over the Internet at 10:00 a.m. Eastern Time on Wednesday, July 24, 2013. This webcast can be accessed from CONMED’s web site at www.conmed.com. Replays of the call will be made available through August 2, 2013.
CONMED profile
CONMED is a medical technology company with an emphasis on surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,600 employees distribute its products worldwide from several manufacturing locations. CONMED has a direct selling presence in 16 countries outside the United States and international sales constitute approximately 50% of the Company’s total sales.
Forward Looking Information
This press release contains forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties. The forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The forward-looking statements in this press release involve risks and uncertainties which could cause actual results, performance or trends, to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct. In addition to general industry and economic conditions, factors that could cause actual results to differ materially from those discussed in the forward-looking statements in this press release include, but are not limited to: (i) the failure of any one or more of the assumptions stated above, to prove to be correct; (ii) the risks relating to forward-looking statements discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2012; (iii) cyclical purchasing patterns from customers, end-users and dealers; (iv) timely release of new products, and acceptance of such new products by the market; (v) the introduction of new products by competitors and other competitive responses; (vi) the possibility that any new acquisition or other transaction may require the Company to reconsider its financial assumptions and goals/targets; (vii) increasing costs for raw material, transportation of litigation; (viii) the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate high standards for screening and/or processing of such tissues; and/or (ix) the Company’s ability to devise and execute strategies to respond to market conditions.
| CONMED News Release Continued | Page 4 of 12 | July 24, 2013 |
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(In thousands except per share amounts)
(unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| Net sales | $ | 189,695 | $ | 192,993 | $ | 384,011 | $ | 380,007 | ||||||||
| Cost of sales | 88,761 | 88,471 | 180,692 | 171,181 | ||||||||||||
| Cost of sales, other – Note A | 1,202 | 1,606 | 2,676 | 3,228 | ||||||||||||
| Gross profit | 99,732 | 102,916 | 200,643 | 205,598 | ||||||||||||
| Selling and administrative | 73,707 | 77,174 | 148,513 | 154,899 | ||||||||||||
| Research and development | 7,192 | 6,591 | 14,287 | 12,285 | ||||||||||||
| Medical device excise tax | — | 1,406 | — | 2,986 | ||||||||||||
| Other expense– Note B | 1,775 | 2,093 | 3,763 | 3,906 | ||||||||||||
| 82,674 | 87,264 | 166,563 | 174,076 | |||||||||||||
| Income from operations | 17,058 | 15,652 | 34,080 | 31,522 | ||||||||||||
| Loss on early extinguishment of debt | — | — | — | 263 | ||||||||||||
| Interest expense | 1,551 | 1,383 | 2,988 | 2,749 | ||||||||||||
| Income before income taxes | 15,507 | 14,269 | 31,092 | 28,510 | ||||||||||||
| Provision for income taxes | 5,211 | 4,736 | 10,828 | 8,485 | ||||||||||||
| Net income | $ | 10,296 | $ | 9,533 | $ | 20,264 | $ | 20,025 | ||||||||
| Per share data: | ||||||||||||||||
| Net income | ||||||||||||||||
| Basic | $ | .36 | $ | .35 | $ | .72 | $ | .72 | ||||||||
| Diluted | .36 | .34 | .71 | .71 | ||||||||||||
| Weighted average common shares | ||||||||||||||||
| Basic | 28,327 | 27,591 | 28,178 | 27,860 | ||||||||||||
| Diluted | 28,672 | 27,983 | 28,577 | 28,258 | ||||||||||||
Note A –Included in cost of sales, other in the three and six months ended June 30, 2012 and 2013 are costs related to the consolidation of our production facilities. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.
Note B – Other expense in the three and six months ended June 30, 2012 and 2013 includes a number of adjusted charges. Refer to the Reconciliation of Reported Net Income to Adjusted Net Income for further details.
| CONMED News Release Continued | Page 5 of 12 | July 24, 2013 |
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS
| December 31, | June 30, | |||||||
| 2012 | 2013 | |||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 23,720 | $ | 38,123 | ||||
| Accounts receivable, net | 139,124 | 140,570 | ||||||
| Inventories | 156,228 | 148,717 | ||||||
| Income taxes receivable | 2,897 | 2,800 | ||||||
| Deferred income taxes | 11,931 | 10,548 | ||||||
| Prepaid expenses and other current assets | 14,993 | 17,848 | ||||||
| Total current assets | 348,893 | 358,606 | ||||||
| Property, plant and equipment, net | 139,041 | 137,612 | ||||||
| Deferred income taxes | 1,057 | 1,166 | ||||||
| Goodwill | 249,160 | 249,160 | ||||||
| Other intangible assets, net | 190,809 | 186,823 | ||||||
| Other assets | 150,547 | 149,653 | ||||||
| Total assets | $ | 1,079,507 | $ | 1,083,020 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Current portion of long-term debt | $ | 1,050 | $ | 1,093 | ||||
| Other current liabilities | 124,164 | 98,062 | ||||||
| Total current liabilities | 125,214 | 99,155 | ||||||
| Long-term debt | 160,802 | 233,017 | ||||||
| Deferred income taxes | 99,857 | 105,630 | ||||||
| Other long-term liabilities | 86,636 | 60,551 | ||||||
| Total liabilities | 472,509 | 498,353 | ||||||
| Shareholders' equity: | ||||||||
| Capital accounts | 256,672 | 223,899 | ||||||
| Retained earnings | 377,907 | 389,620 | ||||||
| Accumulated other comprehensive loss | (27,581 | ) | (28,852 | ) | ||||
| Total equity | 606,998 | 584,667 | ||||||
| Total liabilities and shareholders' equity | $ | 1,079,507 | $ | 1,083,020 | ||||
| CONMED News Release Continued | Page 6 of 12 | July 24, 2013 |
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENTS OF CASH FLOWS
(in thousands)
(unaudited)
| Six months ended | ||||||||
| June 30, | ||||||||
| 2012 | 2013 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income | $ | 20,264 | $ | 20,025 | ||||
| Adjustments to reconcile net income | ||||||||
| to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 23,064 | 23,816 | ||||||
| Stock-based compensation | 2,574 | 2,496 | ||||||
| Loss on early extinguishment of debt | — | 263 | ||||||
| Deferred income taxes | 6,091 | 5,038 | ||||||
| Increase (decrease) in cash flows from changes in assets and liabilities: | ||||||||
| Accounts receivable | (1,027 | ) | (2,689 | ) | ||||
| Inventories | 3,078 | (1,581 | ) | |||||
| Accounts payable | 1,345 | (2,207 | ) | |||||
| Income taxes receivable (payable) | (4,589 | ) | (1,171 | ) | ||||
| Accrued compensation and benefits | (6,730 | ) | (7,393 | ) | ||||
| Other assets | (1,779 | ) | (3,714 | ) | ||||
| Other liabilities | (9,014 | ) | (9,729 | ) | ||||
| Net cash provided by operating activities | 33,277 | 23,154 | ||||||
| Cash flows from investing activities: | ||||||||
| Payments related to distribution agreement | (64,116 | ) | — | |||||
| Purchases of property, plant, and equipment | (11,596 | ) | (8,201 | ) | ||||
| Net cash used in investing activities | (75,712 | ) | (8,201 | ) | ||||
| Cash flows from financing activities: | ||||||||
| Payments on debt | (32,538 | ) | (742 | ) | ||||
| Proceeds of debt | 57,000 | 73,000 | ||||||
| Payments related to distribution agreement | — | (34,000 | ) | |||||
| Dividends paid on common stock | (4,328 | ) | (8,445 | ) | ||||
| Payments related to issuance of debt | — | (1,725 | ) | |||||
| Net proceeds from common stock issued under employee plans | 7,868 | 10,366 | ||||||
| Repurchase of common stock | — | (44,729 | ) | |||||
| Other, net | 4,925 | 7,090 | ||||||
| Net cash provided by financing activities | 32,927 | 815 | ||||||
| Effect of exchange rate change on cash and cash equivalents | (294 | ) | (1,365 | ) | ||||
| Net increase (decrease) in cash and cash equivalents | (9,802 | ) | 14,403 | |||||
| Cash and cash equivalents at beginning of period | 26,048 | 23,720 | ||||||
| Cash and cash equivalents at end of period | $ | 16,246 | $ | 38,123 | ||||
| CONMED News Release Continued | Page 7 of 12 | July 24, 2013 |
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME
Three Months Ended June 30, 2012 and 2013
(In thousands except per share amounts)
(unaudited)
| 2012 | 2013 | |||||||
| Reported net income | $ | 10,296 | $ | 9,533 | ||||
| Facility consolidation costs included in cost of sales | 1,202 | 1,606 | ||||||
| Administrative consolidation costs included in other expense | 1,231 | 1,566 | ||||||
| Legal arbitration and patent dispute costs included in other expense | 544 | 527 | ||||||
| Total other expense | 1,775 | 2,093 | ||||||
| Adjusted expense before income taxes | 2,977 | 3,699 | ||||||
| Provision (benefit) for income taxes on adjusted expenses | (1,072 | ) | (1,332 | ) | ||||
| Adjusted net income | $ | 12,201 | $ | 11,900 | ||||
| Per share data: | ||||||||
| Reported net income | ||||||||
| Basic | $ | 0.36 | $ | 0.35 | ||||
| Diluted | 0.36 | 0.34 | ||||||
| Adjusted net income | ||||||||
| Basic | $ | 0.43 | $ | 0.43 | ||||
| Diluted | 0.43 | 0.43 | ||||||
Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above.
| CONMED News Release Continued | Page 8 of 12 | July 24, 2013 |
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO ADJUSTED NET INCOME
Six Months Ended June 30, 2012 and 2013
(In thousands except per share amounts)
(unaudited)
| 2012 | 2013 | |||||||
| Reported net income | $ | 20,264 | $ | 20,025 | ||||
| Facility consolidation costs included in cost of sales | 2,676 | 3,228 | ||||||
| Administrative consolidation costs included in other expense | 1,504 | 3,170 | ||||||
| Costs associated with purchase of Nordic region distributor | 704 | — | ||||||
| Legal arbitration and patent dispute costs included in other expense | 1,555 | 736 | ||||||
| Total other expense | 3,763 | 3,906 | ||||||
| Loss on early extinguishment of debt | — | 263 | ||||||
| Adjusted expense before income taxes | 6,439 | 7,397 | ||||||
| Provision (benefit) for income taxes on adjusted expenses | (2,318 | ) | (2,663 | ) | ||||
| Adjusted net income | $ | 24,385 | $ | 24,759 | ||||
| Per share data: | ||||||||
| Reported net income | ||||||||
| Basic | $ | 0.72 | $ | 0.72 | ||||
| Diluted | 0.71 | 0.71 | ||||||
| Adjusted net income | ||||||||
| Basic | $ | 0.87 | $ | 0.89 | ||||
| Diluted | 0.85 | 0.88 | ||||||
Management has provided the above reconciliation of net income to adjusted net income as an additional measure that investors can use to compare operating performance between reporting periods. Management believes this reconciliation provides a useful presentation of operating performance as discussed in the section “Use of Non-GAAP Financial Measures” above.
| CONMED News Release Continued | Page 9 of 12 | July 24, 2013 |
CONMED CORPORATION
RECONCILIATION OF INCOME FROM OPERATIONS TO ADJUSTED INCOME FROM OPERATIONS
(In thousands)
(unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| Reported income from operations | $ | 17,058 | $ | 15,652 | $ | 34,080 | $ | 31,522 | ||||||||
| Facility consolidation costs included in cost of sales | 1,202 | 1,606 | 2,676 | 3,228 | ||||||||||||
| Administrative consolidation costs included in other expense | 1,231 | 1,566 | 1,504 | 3,170 | ||||||||||||
| Medical device excise tax | — | 1,406 | — | 2,986 | ||||||||||||
| Costs associated with purchase of Nordic region distributor | — | — | 704 | — | ||||||||||||
| Legal arbitration and patent dispute costs included in other expense | 544 | 527 | 1,555 | 736 | ||||||||||||
| Adjusted income from operations | $ | 20,035 | $ | 20,757 | $ | 40,519 | $ | 41,642 | ||||||||
| Operating Margin | ||||||||||||||||
| Reported | 9.0% | 8.1% | 8.9% | 8.3% | ||||||||||||
| Adjusted | 10.6% | 10.8% | 10.6% | 11.0% | ||||||||||||
Management has provided the above reconciliation as an additional measure that investors can use to compare financial results between reporting periods. Management believes this reconciliation provides a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.
| CONMED News Release Continued | Page 10 of 12 | July 24, 2013 |
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO EBITDA & ADJUSTED EBITDA
(in thousands)
(unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2012 | 2013 | 2012 | 2013 | |||||||||||||
| Net income | $ | 10,296 | $ | 9,533 | $ | 20,264 | $ | 20,025 | ||||||||
| Provision for income taxes | 5,211 | 4,736 | 10,828 | 8,485 | ||||||||||||
| Interest expense | 1,551 | 1,383 | 2,988 | 2,749 | ||||||||||||
| Loss on early extinguishment of debt | — | — | — | 263 | ||||||||||||
| Depreciation | 4,586 | 4,549 | 9,274 | 9,168 | ||||||||||||
| Amortization | 6,459 | 7,389 | 13,423 | 14,381 | ||||||||||||
| EBITDA | $ | 28,103 | $ | 27,590 | $ | 56,777 | $ | 55,071 | ||||||||
| Stock-based compensation | 1,391 | 1,344 | 2,574 | 2,496 | ||||||||||||
| Facility consolidation costs included in cost of sales | 1,202 | 1,606 | 2,676 | 3,228 | ||||||||||||
| Administrative consolidation costs included in other expense | 1,231 | 1,566 | 1,504 | 3,170 | ||||||||||||
| Costs associated with purchase of Nordic region distributor | — | — | 704 | — | ||||||||||||
| Legal arbitration and patent dispute costs included in other expense | 544 | 527 | 1,555 | 736 | ||||||||||||
| Adjusted EBITDA | $ | 32,471 | $ | 32,633 | $ | 65,790 | $ | 64,701 | ||||||||
| EBITDA Margin | ||||||||||||||||
| EBITDA | 14.8% | 14.3% | 14.8% | 14.5% | ||||||||||||
| Adjusted EBITDA | 17.1% | 16.9% | 17.1% | 17.0% | ||||||||||||
Management has provided the above reconciliations as additional measures that investors can use to compare financial results between reporting periods. Management believes these reconciliations provide a useful presentation of financial measures as discussed in the section “Use of Non-GAAP Financial Measures” above.
| CONMED News Release Continued | Page 11 of 12 | July 24, 2013 |
CONMED CORPORATION
Second Quarter Sales Summary
(in millions)
| Three Months Ended June 30, | ||||||||||||||||
| Constant | ||||||||||||||||
| Currency | ||||||||||||||||
| 2012 | 2013 | Growth | Growth | |||||||||||||
| Orthopedic surgery | $ | 103.8 | $ | 101.8 | -1.9% | -1.1% | ||||||||||
| General surgery | 71.6 | 73.2 | 2.2% | 2.7% | ||||||||||||
| Surgical visualization | 14.3 | 18.0 | 25.9% | 25.2% | ||||||||||||
| $ | 189.7 | $ | 193.0 | 1.7% | 2.3% | |||||||||||
| Single-use products | $ | 153.6 | $ | 153.8 | 0.1% | 0.7% | ||||||||||
| Capital products | 36.1 | 39.2 | 8.6% | 9.2% | ||||||||||||
| $ | 189.7 | $ | 193.0 | 1.7% | 2.3% | |||||||||||
| CONMED News Release Continued | Page 12 of 12 | July 24, 2013 |
CONMED CORPORATION
Six Months Sales Summary
(in millions)
| Six Months Ended June 30, | ||||||||||||||||
| Constant | ||||||||||||||||
| Currency | ||||||||||||||||
| 2012 | 2013 | Growth | Growth | |||||||||||||
| Orthopedic surgery | $ | 210.7 | $ | 206.9 | -1.8% | -1.2% | ||||||||||
| General surgery | 141.0 | 140.0 | -0.7% | -0.4% | ||||||||||||
| Surgical visualization | 32.3 | 33.1 | 2.5% | 3.1% | ||||||||||||
| $ | 384.0 | $ | 380.0 | -1.0% | -0.5% | |||||||||||
| Single-use products | $ | 307.2 | $ | 301.6 | -1.8% | -1.3% | ||||||||||
| Capital products | 76.8 | 78.4 | 2.1% | 2.6% | ||||||||||||
| $ | 384.0 | $ | 380.0 | -1.0% | -0.5% | |||||||||||